BeOne Medicines (ONC) Intangibles (2017 - 2026)
BeOne Medicines (ONC) posted quarterly Intangibles of $61.7 million for Q1 2026, up 23.02% year-over-year from $50.1 million in Q1 2025, and down 1.63% quarter-over-quarter from $62.7 million in Q4 2025.
BeOne Medicines (ONC) Intangibles (2017 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Intangibles for 10 consecutive years, with $61.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles rose 23.02% year-over-year to $61.7 million; the TTM figure through Mar 2026 stood at $61.7 million (up 23.02% YoY), while the FY2025 annual figure was $62.7 million, up 22.72% from the prior year.
- Intangibles retreated to $61.7 million in Q1 2026 per ONC's latest filing, from $62.7 million in the prior quarter.
- Across five years, Intangibles topped out at $64.9 million in Q2 2025 and bottomed at $39.7 million in Q1 2023.
- Historically, Intangibles has averaged $52.1 million across 5 years, with a median of $53.7 million in 2023.
- Annual changes were most pronounced in 2022 — Intangibles surged 851.73% — and 2023, when it fell 13.26%.
- BeOne Medicines' Intangibles stood at $40.6 million in 2022, then soared by 40.68% to $57.1 million in 2023, then decreased by 10.58% to $51.1 million in 2024, then advanced by 22.72% to $62.7 million in 2025, then decreased by 1.63% to $61.7 million in 2026.
- Business Quant data shows ONC's Intangibles at $61.7 million in Q1 2026, $62.7 million in Q4 2025, and $63.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.96 Mn |
| Mar 31, 2026 | 61.68 Mn |
| Dec 31, 2025 | 62.70 Mn |
| Sep 30, 2025 | 63.58 Mn |
| Jun 30, 2025 | 64.89 Mn |
| Mar 31, 2025 | 50.14 Mn |
| Dec 31, 2024 | 51.10 Mn |
| Sep 30, 2024 | 53.94 Mn |
| Jun 30, 2024 | 53.72 Mn |
| Mar 31, 2024 | 55.17 Mn |
| Dec 31, 2023 | 57.14 Mn |
| Sep 30, 2023 | 53.66 Mn |
| Jun 30, 2023 | 46.90 Mn |
| Mar 31, 2023 | 39.74 Mn |
| Dec 31, 2022 | 40.62 Mn |
| Sep 30, 2022 | 40.85 Mn |
| Jun 30, 2022 | 43.33 Mn |
| Mar 31, 2022 | 45.81 Mn |
| Dec 31, 2021 | 46.68 Mn |
| Sep 30, 2021 | 14.10 Mn |